{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:54:23Z","timestamp":1776704063056,"version":"3.51.2"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1212\/wnl.53.6.1170","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:41:46Z","timestamp":1336916506000},"page":"1170-1170","source":"Crossref","is-referenced-by-count":17,"title":["Carbamazepine in comparative trials"],"prefix":"10.1212","volume":"53","author":[{"given":"Santiago","family":"Arroyo","sequence":"first","affiliation":[{"name":"From the Servicio de Neurologi\u0301a (Dr. Arroyo)Hospital Clinic de Barcelona, Spain; and the Institute of Neurology (Dr. Sander), University College London, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josemir W. A. S.","family":"Sander","sequence":"additional","affiliation":[{"name":"From the Servicio de Neurologi\u0301a (Dr. Arroyo)Hospital Clinic de Barcelona, Spain; and the Institute of Neurology (Dr. Sander), University College London, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562659"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.61.719.779"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00547561"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198005060-00006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04089.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02932.x"},{"key":"e_1_3_2_10_2","first-page":"189","volume":"11","year":"1974","unstructured":"Hooper WD, Dubetz DK, Eadie MJ, Tyrer JH. Preliminary observations on the clinical pharmacology of carbamazepine (\u2018Tegretol\u2019). Proc Aust Assoc Neurol 1974;11:189\u2013198.","journal-title":"Proc Aust Assoc Neurol"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06152.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198312000-00009"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199105000-00003"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1986.00520030053013"},{"key":"e_1_3_2_15_2","unstructured":"Cereghino JJ. Serum carbamazepine concentration and clinical control. In: Penry JK Daly D eds. Complex partial seizures and their treatment. New York:Raven Press 1975:309\u2013330."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1976.tb03394.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.27.6.511"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.7.904"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04319.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.9.1252"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.7.639"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(89)90070-3"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1988.tb04237.x"},{"key":"e_1_3_2_24_2","first-page":"247","volume":"18","year":"1980","unstructured":"Pynnonen S, Frey H, Sillanpaa M. The auto-induction of carbamazepine during long-term therapy. Int J Clin Pharmacol Ther Toxicol 1980;18:247\u2013252.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.24.5.401"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250215"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.542"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.6.682"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540340081016"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb01793.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00003"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199005000-00004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(96)00011-3"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198412000-00005"},{"key":"e_1_3_2_37_2","first-page":"199","volume":"32","year":"1978","unstructured":"Suzuki K, Kaneko S, Sato T. Time-dependency of serum carbamazepine concentration. Folia Psychiatr Neurol Jpn 1978;32:199\u2013209.","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420220087032"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.44"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00782.x"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)21671-8","volume":"231","year":"1984","unstructured":"Bourgeois BF, Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J Pharmacol Exp Ther 1984;231:411\u2013415.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1990.00530080072013"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04210080006004"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04089.x"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562904"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250215"},{"key":"e_1_3_2_48_2","first-page":"29","volume":"94","year":"1983","unstructured":"Andersen EB, Philbert A, Klee JG. Carbamazepine monotherapy in epileptic outpatients. Acta Neurol Scand Suppl 1983;94:29\u201334.","journal-title":"Acta Neurol Scand Suppl"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.6.642"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90945-1"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1979.00500370052010"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1974.tb04028.x"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1995.tb11978.x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90945-1"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(88)90007-1"},{"key":"e_1_3_2_56_2","first-page":"226","volume":"23","year":"1985","unstructured":"Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1985;23:226\u2013232.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01372.x"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(98)80067-8"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/00115677-199804060-00001"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.53.6.1170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:47:30Z","timestamp":1743115650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.53.6.1170"}},"subtitle":["Pharmacokinetic characteristics too often forgotten"],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1212\/WNL.53.6.1170"],"URL":"https:\/\/doi.org\/10.1212\/wnl.53.6.1170","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}